Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer

Chengfei Liu, Cameron Armstrong, Yezi Zhu, Wei Lou, Allen C Gao

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Considerable evidence from both clinical and experimental studies suggests that androgen receptor variants, particularly androgen receptor variant 7 (AR-V7), are critical in the induction of resistance to enzalutamide and abiraterone. In this study, we investigated the role of AR-V7 in the cross-resistance of enzalutamide and abiraterone and examined if inhibition of AR-V7 can improve abiraterone treatment response. We found that enzalutamide-resistant cells are cross-resistant to abiraterone, and that AR-V7 confers resistance to abiraterone. Knock down of AR-V7 by siRNA in abiraterone resistant CWR22Rv1 and C4-2B MDVR cells restored their sensitivity to abiraterone, indicating that AR-V7 is involved in abiraterone resistance. Abiraterone resistant prostate cancer cells generated by chronic treatment with abiraterone showed enhanced AR-V7 protein expression. Niclosamide, an FDAapproved antihelminthic drug that has been previously identified as a potent inhibitor of AR-V7, re-sensitizes resistant cells to abiraterone treatment in vitro and in vivo. In summary, this preclinical study suggests that overexpression of AR-V7 contributes to resistance to abiraterone, and supports the development of combination of abiraterone with niclosamide as a potential treatment for advanced castration resistant prostate cancer.

Original languageEnglish (US)
Pages (from-to)32210-32220
Number of pages11
JournalOncotarget
Volume7
Issue number22
DOIs
StatePublished - May 31 2016

Fingerprint

Niclosamide
Castration
Androgen Receptors
Prostatic Neoplasms
abiraterone

Keywords

  • Abiraterone
  • Androgen receptor variant
  • Niclosamide
  • Prostate cancer
  • Resistance

ASJC Scopus subject areas

  • Oncology

Cite this

Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer. / Liu, Chengfei; Armstrong, Cameron; Zhu, Yezi; Lou, Wei; Gao, Allen C.

In: Oncotarget, Vol. 7, No. 22, 31.05.2016, p. 32210-32220.

Research output: Contribution to journalArticle

Liu, Chengfei ; Armstrong, Cameron ; Zhu, Yezi ; Lou, Wei ; Gao, Allen C. / Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer. In: Oncotarget. 2016 ; Vol. 7, No. 22. pp. 32210-32220.
@article{b5d22b21be4648979e4be404cc21f3c3,
title = "Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer",
abstract = "Considerable evidence from both clinical and experimental studies suggests that androgen receptor variants, particularly androgen receptor variant 7 (AR-V7), are critical in the induction of resistance to enzalutamide and abiraterone. In this study, we investigated the role of AR-V7 in the cross-resistance of enzalutamide and abiraterone and examined if inhibition of AR-V7 can improve abiraterone treatment response. We found that enzalutamide-resistant cells are cross-resistant to abiraterone, and that AR-V7 confers resistance to abiraterone. Knock down of AR-V7 by siRNA in abiraterone resistant CWR22Rv1 and C4-2B MDVR cells restored their sensitivity to abiraterone, indicating that AR-V7 is involved in abiraterone resistance. Abiraterone resistant prostate cancer cells generated by chronic treatment with abiraterone showed enhanced AR-V7 protein expression. Niclosamide, an FDAapproved antihelminthic drug that has been previously identified as a potent inhibitor of AR-V7, re-sensitizes resistant cells to abiraterone treatment in vitro and in vivo. In summary, this preclinical study suggests that overexpression of AR-V7 contributes to resistance to abiraterone, and supports the development of combination of abiraterone with niclosamide as a potential treatment for advanced castration resistant prostate cancer.",
keywords = "Abiraterone, Androgen receptor variant, Niclosamide, Prostate cancer, Resistance",
author = "Chengfei Liu and Cameron Armstrong and Yezi Zhu and Wei Lou and Gao, {Allen C}",
year = "2016",
month = "5",
day = "31",
doi = "10.18632/oncotarget.8493",
language = "English (US)",
volume = "7",
pages = "32210--32220",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "22",

}

TY - JOUR

T1 - Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer

AU - Liu, Chengfei

AU - Armstrong, Cameron

AU - Zhu, Yezi

AU - Lou, Wei

AU - Gao, Allen C

PY - 2016/5/31

Y1 - 2016/5/31

N2 - Considerable evidence from both clinical and experimental studies suggests that androgen receptor variants, particularly androgen receptor variant 7 (AR-V7), are critical in the induction of resistance to enzalutamide and abiraterone. In this study, we investigated the role of AR-V7 in the cross-resistance of enzalutamide and abiraterone and examined if inhibition of AR-V7 can improve abiraterone treatment response. We found that enzalutamide-resistant cells are cross-resistant to abiraterone, and that AR-V7 confers resistance to abiraterone. Knock down of AR-V7 by siRNA in abiraterone resistant CWR22Rv1 and C4-2B MDVR cells restored their sensitivity to abiraterone, indicating that AR-V7 is involved in abiraterone resistance. Abiraterone resistant prostate cancer cells generated by chronic treatment with abiraterone showed enhanced AR-V7 protein expression. Niclosamide, an FDAapproved antihelminthic drug that has been previously identified as a potent inhibitor of AR-V7, re-sensitizes resistant cells to abiraterone treatment in vitro and in vivo. In summary, this preclinical study suggests that overexpression of AR-V7 contributes to resistance to abiraterone, and supports the development of combination of abiraterone with niclosamide as a potential treatment for advanced castration resistant prostate cancer.

AB - Considerable evidence from both clinical and experimental studies suggests that androgen receptor variants, particularly androgen receptor variant 7 (AR-V7), are critical in the induction of resistance to enzalutamide and abiraterone. In this study, we investigated the role of AR-V7 in the cross-resistance of enzalutamide and abiraterone and examined if inhibition of AR-V7 can improve abiraterone treatment response. We found that enzalutamide-resistant cells are cross-resistant to abiraterone, and that AR-V7 confers resistance to abiraterone. Knock down of AR-V7 by siRNA in abiraterone resistant CWR22Rv1 and C4-2B MDVR cells restored their sensitivity to abiraterone, indicating that AR-V7 is involved in abiraterone resistance. Abiraterone resistant prostate cancer cells generated by chronic treatment with abiraterone showed enhanced AR-V7 protein expression. Niclosamide, an FDAapproved antihelminthic drug that has been previously identified as a potent inhibitor of AR-V7, re-sensitizes resistant cells to abiraterone treatment in vitro and in vivo. In summary, this preclinical study suggests that overexpression of AR-V7 contributes to resistance to abiraterone, and supports the development of combination of abiraterone with niclosamide as a potential treatment for advanced castration resistant prostate cancer.

KW - Abiraterone

KW - Androgen receptor variant

KW - Niclosamide

KW - Prostate cancer

KW - Resistance

UR - http://www.scopus.com/inward/record.url?scp=84973572847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973572847&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.8493

DO - 10.18632/oncotarget.8493

M3 - Article

C2 - 27049719

AN - SCOPUS:84973572847

VL - 7

SP - 32210

EP - 32220

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 22

ER -